|Bid||14.24 x 800|
|Ask||14.29 x 2200|
|Day's Range||13.51 - 14.37|
|52 Week Range||9.74 - 27.82|
|Beta (5Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.44|
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights and will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details of both events are as follows:
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Those following along with Epizyme, Inc. (NASDAQ:EPZM) will no doubt be intrigued by the recent purchase of shares by...
Shares of Epizyme Inc. were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or refractory follicular lymphoma. Tazverik was first approved by the FDA in January, to treat epithelioid sarcoma. "In our view, there remains no clear standard of care in the relapsed and/or refractory FL population as not all patients benefit from today's available therapies," Dr. Shefali Agarwal, Epizyme's chief medical officer of Epizyme, said in a news release. The monthly list price is $15,500 for all approved indications, a spokesperson for the company said in an email. However, the labels for the two new indications are narrower than some analysts had expected. "We believe this label may disappoint some investors who had expected a broad, biomarker agnostic label in the 3L setting," SVB Leerink's Andrew Berens wrote in a note. Other analysts see a rosier future for the drug, with Wedbush analysts saying "we believe meaningful adoption will occur without the genetic test based on the drug's competitive clinical profile." Epizyme's stock has declined 16.8% since the start of the year. The S&P 500 is down 3.5.%.
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Investors with extra cash on the sidelines may be able to capture some exciting cancer stocks at attractive prices. One company received approval from the Food and Drug Administration (FDA) for its cancer drug and is expanding to other indications. Another offers a promising pipeline with a strong patent portfolio that is in the process of regulatory submission.
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program
On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; Dr. Shefali Agarwal, Chief Medical Officer; and Paolo Tombesi, Chief Financial Officer who will join us for the Q&A session. This approval made TAZVERIK the first and only FDA-approved treatment specifically indicated for epithelioid sarcoma patients and the first and only approved EZH2 inhibitor on the market.
Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.Quarterly Results Earnings per share fell 30.77% over the past year to ($0.51), which beat the estimate of ($0.74).Revenue of $1,354,000 less by 82.84% from the same period last year, which missed the estimate of $3,680,000.Guidance Epizyme hasn't issued any earnings guidance for the time being.Epizyme hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: May 04, 2020View more earnings on EPZMTime: 03:04 AM ETWebcast URL: https://edge.media-server.com/mmc/p/shejfym8Price Action Company's 52-week high was at $27.82Company's 52-week low was at $9.73Price action over last quarter: down 26.71%Company Profile Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.See more from Benzinga * Stocks That Hit 52-Week Lows On Friday * Price Over Earnings Overview: Michaels Companies * Morning Market Stats in 5 Minutes(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2020 financial results.
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2020 financial results and other business highlights on Monday, May 4, 2020 at 9:00 a.m. ET.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
A week ago, Epizyme, Inc. (NASDAQ:EPZM) came out with a strong set of yearly numbers that could potentially lead to a...